Abstract Library

#4635 Comparison of 18F-DOPA PET/CT and 68Ga-DOTATOC PET/CT and their impact on response to PRRT in midgut neuroendocrine tumours

Introduction: 18F-DOPA PET/CT is a powerful diagnostic test for assessing tumour burden in midgut neuroendocrine tumours (NETs). 68Ga-DOTATOC PET/CT is required for patient selection for PRRT.

Conference:

Presenting Author: Longo M

Authors: Longo M, Coccarelli A, Henry T, Kamoun T, Morbelli S,

Keywords: F-DOPA, Ga-DOTATOC, PRRT, midgut,

#4634 Management of hypercalcaemia of malignancy in neuroendocrine tumour patients – A case series

Introduction: Hypercalcaemia of malignancy (HM) rarely coexists with neuroendocrine tumours (NET). There are no precise guidelines for management of hypercalcaemia in NET.

Conference:

Presenting Author:

Authors: Klepinowska M, Sagan K, Brzeska A, Andrysiak-Mamos E, Kiedrowicz B,

Keywords: hypercalcaemia of malignancy, neuroendocrine tumour, pancreatic neuroendocrine tumour, hypercalcaemia,

#4582 Potential significance of individual dosimetry of radionuclide therapy (RLT) using [177Lu]Lu-DOTA-TATE or mixture of [177Lu/90Y]-DOTA-TATE in NET therapy

Introduction: RTL targeted somatostatin receptors is increasingly available. Individual dosimetry performed during RLT of NET may enable to achieve better results of therapy with maintaining its safety.

Conference:

Presenting Author: Opalińska M

Authors: Opalinska M, Kaminski G, Dedecjus M, Kowalska A, Kolodziej M,

Keywords: RLT, DUONEN, GEP-NET, Tandem RLT, dosimetry,

#4569 Dramatic response to tarlatamab in a patient with metastatic primary small cell neuroendocrine carcinoma of the breast

Introduction: Primary small cell neuroendocrine carcinoma of the breast (SCNCB) is a rare malignancy with a poor prognosis. Tarlatamab, a DLL3-targeted bispecific T-cell engager, is FDA-approved for extensive-stage small cell lung carcinoma.

Conference:

Presenting Author: Patel D

Authors: Patel D, Alahmadi A, Maddocks K, Lampert B, Giglio P,

Keywords: tarlatamab, small cell neuroendocrine carcinoma of the breast,

#4567 Malignant pheochromocytoma with late distant metastases and secondary hypercalcaemia

Introduction: Pheochromocytoma is a rare neuroendocrine tumour of the adrenal medulla. Malignant variants occur with a very low frequency and can be diagnosed only after the spread of distant metastasis.

Conference:

Presenting Author:

Authors: Kirova I, Vandeva S, Markova M, Elenkova A, Robeva R,

Keywords: neuroendocrine, malignant pheochromocytoma, metastasis, hypercalcaemia,